Aprea Therapeutics Inc (APRE)

Aug 15, 2026

Maxim Group Maintains Aprea Therapeutics(APRE.US) With Buy Rating, Maintains Target Price $5 - Moomoo

Aug 15, 2026

Aug 12, 2026

Aprea Therapeutics Releases Q2 2026 Financial Results - AlphaStreet

Aug 12, 2026

Aug 12, 2026

Aprea Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com

Aug 12, 2026

Aug 12, 2026

Aprea Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 12, 2026

Aug 12, 2026

Form 8K Aprea Therapeutics Inc For: 12 August By Investing.com - Investing.com Nigeria

Aug 12, 2026

Aug 12, 2026

Aprea Therapeutics advances APR-1051 oncology pipeline progress - tipranks.com

Aug 12, 2026

Aug 12, 2026

Form 8K Aprea Therapeutics Inc For: 12 August - Investing.com India

Aug 12, 2026

Aug 12, 2026

Aprea Therapeutics 2Q 2026: Revenue $0 Net loss $(3.59M), EPS $(0.07) — 10-Q Summary - TradingView

Aug 12, 2026

Aug 12, 2026

Aprea Therapeutics (NASDAQ: APRE) extends cash runway with $41M balance and trial updates - Stock Titan

Aug 12, 2026

Aug 12, 2026

Aprea Therapeutics Announces Second Quarter 2026 Financial Results - The Manila Times

Aug 12, 2026

Aug 12, 2026

Aprea Therapeutics Reports $3.6 Million Q2 Net Loss - Quiver Quantitative

Aug 12, 2026

Aug 12, 2026

Aprea Therapeutics Q2 net loss widens on higher R&D costs - TradingView

Aug 12, 2026

Aug 10, 2026

Aprea Therapeutics Inc (APRE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Aug 10, 2026

Aug 09, 2026

Price to earnings forward of Aprea Therapeutics, Inc. – NASDAQ:APRE - TradingView

Aug 09, 2026

Aug 07, 2026

Aprea Therapeutics Inc (APRE) Stock News Today - TradingKey

Aug 07, 2026

Aug 07, 2026

Aprea Therapeutics Inc expected to post a loss of 23 cents a shareEarnings Preview - TradingView

Aug 07, 2026

Aug 07, 2026

Aprea Therapeutics, Inc. (APRE) stock price, news, quote and history - Yahoo Finance Singapore

Aug 07, 2026

Aug 05, 2026

Aprea Expands APR-1051 Trial as Enrollment Accelerates - MyChesCo

Aug 05, 2026

Aug 05, 2026

APRE Q2'26 Earnings: EPS estimate is (0.18) USD - TradingView

Aug 05, 2026

Aug 04, 2026

Aprea’s ATRN-119 Trial Completion: What It Means For APRE Investors - TipRanks

Aug 04, 2026

Aug 02, 2026

APRE Q1 2026 Earnings: Narrower-than-Expected Loss Beats Estimates, Shares Slide 2.36%High Growth Earnings - dars.gov.et

Aug 02, 2026

Jul 30, 2026

Aprea Therapeutics plans Q4 2026 data update for APR-1051 trial - Investing.com Nigeria

Jul 30, 2026

Jul 30, 2026

Aprea Therapeutics Provides ACESOT-1051 Program Update for WEE1 Inhibitor APR-1051: Accelerating and Expanding Enrollment. Clinical Data Presentation Planned for Q4 2026 - The Manila Times

Jul 30, 2026

Jul 29, 2026

Q&A: Aprea Therapeutics' Oren Gilad on WEE1 Inhibitor Data and the Company's DNA Damage Response Strategy - BioPharm International

Jul 29, 2026

Jul 28, 2026

Aprea Therapeutics Inc (APRE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

Jul 28, 2026

Jul 28, 2026

Aprea Therapeutics Inc (APRE) Institutional Confidence - TradingKey

Jul 28, 2026

Jul 27, 2026

APRE|Aprea Therapeutics Inc|Price:0.620|Chg%:-0.012 - TradingKey

Jul 27, 2026

Jul 27, 2026

Aprea Therapeutics Inc (APRE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Jul 27, 2026

Jul 27, 2026

Aprea Therapeutics Inc (APRE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Jul 27, 2026

Jul 27, 2026

TradingKey - TradingKey

Jul 27, 2026

Jul 26, 2026

Aprea Therapeutics Inc (APRE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Jul 26, 2026

Jul 25, 2026

APRE|Aprea Therapeutics Inc|Price:0.632|Chg%:+0.004 - TradingKey

Jul 25, 2026

Jul 25, 2026

Aprea Therapeutics Inc (APRE) Cash Flow - TradingKey

Jul 25, 2026

Jul 23, 2026

Aprea Therapeutics (NASDAQ: APRE) wins 180-day extension to meet $1 bid - Stock Titan

Jul 23, 2026

Jul 22, 2026

Aprea Therapeutics (APRE) Edges Higher with Modest Gains Amid Tight Trading RangeMedian Line - dars.gov.et

Jul 22, 2026

Jul 20, 2026

Aprea Therapeutics(APRE) Stock Options Chain | Quotes & News - Moomoo

Jul 20, 2026

Jul 18, 2026

Aprea Therapeutics Stock Rises After Company Reports Second Unconfirmed Case Of Tumor Reduction In Trial - Stocktwits

Jul 18, 2026

Jul 06, 2026

Enterprise value to EBITDA forward of Aprea Therapeutics, Inc. – NASDAQ:APRE - TradingView

Jul 06, 2026

Jun 26, 2026

APRE Forecast — Price Target — Prediction for 2027 - TradingView

Jun 26, 2026

Jun 26, 2026

Aprea Therapeutics, Inc. Actuals & Estimates (NASDAQ:APRE) - TradingView

Jun 26, 2026

Jun 22, 2026

Precision Medicine Strategies Expand Opportunities for Targeted Cancer Treatment, Says Dr Oren Gilad, Aprea Therapeutics - BioPharm International

Jun 22, 2026

Jun 18, 2026

Aprea Shareholders Approve Directors, Reverse Split Flexibility - The Globe and Mail

Jun 18, 2026

Jun 18, 2026

Aprea Therapeutics Inc (APRE) Valuation: PE, PB & Fair Value Analysis - TradingKey

Jun 18, 2026

Jun 18, 2026

Aprea Therapeutics Shareholders Approve Reverse Stock Split and Key Proposals at 2026 Annual Meeting - Minichart

Jun 18, 2026

Jun 18, 2026

Aprea Therapeutics Inc (APRE) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

Jun 18, 2026

Jun 18, 2026

Aprea Therapeutics Inc (APRE) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Jun 18, 2026

Jun 17, 2026

Aprea Therapeutics shareholders approve director elections and reverse stock split - Investing.com Nigeria

Jun 17, 2026

Jun 17, 2026

Aprea Therapeutics shareholders approve director elections and reverse stock split By Investing.com - Investing.com South Africa

Jun 17, 2026

Jun 16, 2026

APRE: All agenda items, including director elections and reverse stock split, were approved - TradingView

Jun 16, 2026

Jun 15, 2026

Oppenheimer Initiates Aprea Therapeutics(APRE.US) With Buy Rating, Announces Target Price $5 - Moomoo

Jun 15, 2026